RetinalGenix Technologies Inc., a developmental-stage company specializing in ophthalmic screening and pharmacogenetic mapping, has entered into an agreement with LabCorp to support its DNA/RNA/GPS Pharmaco-Genetic Mapping platform. This collaboration aims to make genetic testing and high-resolution retinal imaging more accessible and cost-effective, reducing the need for expensive diagnostics like MRI and CT scans. The initiative is designed to allow early detection of eye and systemic diseases, enhancing diagnostic accuracy and broadening access to screening services. Patients will manage their appointments and test orders online, with results securely released after payment validation at LabCorp centers.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.